Read More Pharma Industry News Foresee Pharmaceuticals licenses MMP-12 pipeline to Primevera in $594m reset to double down on CAMCEVI and injectables Foresee signs $594 million licensing deal with Primevera Therapeutics to exit MMP-12 R&D and focus on CAMCEVI injectables. Read what this signals for biotech strategy. bySrinathJanuary 12, 2026